Molecular characterisation of triple negative essential thrombocythaemia patients by platelet analysis and targeted sequencing
- PMID: 27564461
- PMCID: PMC5022184
- DOI: 10.1038/bcj.2016.75
Molecular characterisation of triple negative essential thrombocythaemia patients by platelet analysis and targeted sequencing
References
-
- Cazzola M, Kralovics R. From Janus kinase 2 to calreticulin: the clinically relevant genomic landscape of myeloproliferative neoplasms. Blood 2014; 123: 3714–3719. - PubMed
-
- Toyama K, Karasawa M, Yamane A, Irisawa H, Yokohama A, Saitoh T et al. JAK2-V617F mutation analysis of granulocytes and platelets from patients with chronic myeloproliferative disorders: advantage of studying platelets. Br J Haematol 2007; 139: 64–69. - PubMed
-
- Toyama K, Karasawa M, Yokohama A, Mitsui T, Uchiumi H, Saitoh T et al. Differences in the JAK2 and MPL mutation status in the cell lineages of the bcr/abl-negative chronic myeloproliferative neoplasm subtypes. Intern Med 2011; 50: 2557–2561. - PubMed
-
- Heller PG, Lev PR, Salim JP, Kornblihtt LI, Goette NP, Chazarreta CD et al. JAK2V617F mutation in platelets from essential thrombocythemia patients: correlation with clinical features and analysis of STAT5 phosphorylation status. Eur J Haematol 2006; 77: 210–216. - PubMed
-
- Campbell PJ, Scott LM, Buck G, Wheatley K, East CL, Marsden JT et al. Definition of subtypes of essential thrombocythaemia and relation to polycythaemia vera based on JAK2 V617F mutation status: a prospective study. Lancet 2005; 366: 1945–1953. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials
Miscellaneous
